Upgrade to SI Premium - Free Trial

Oppenheimer Reiterates Outperform Rating on Biogen (BIIB): "continue to view SMA as an important franchise"

March 11, 2026 4:54 PM
Oppenheimer analyst Jay Olson reiterated an Outperform rating and $250.00 price target on Biogen (NASDAQ: BIIB)The analyst commented, "BIIB reported ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Categories

Analyst Comments